Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT ID: NCT02601612

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-31
• Study Completion Date: 2018-04-26

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants and children.

Detailed Description

Human RSV is the most common viral cause of serious acute lower respiratory illness (LRI) in infants and children under 5 years of age worldwide. This study will evaluate the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants and children. The vaccine will be evaluated in a stepwise fashion beginning in RSV-seropositive children (Group 1), and then in RSV-seronegative infants and children (Group 2). In each group, participants will be randomly assigned to receive a single dose of D46cpΔM2-2 vaccine or placebo at study entry (day 0).

Participants will be enrolled in the study between April 1 and October 31, outside of the RSV season. Group 1 (RSV-seropositive children) will attend several study visits and will be followed for 28 days. Group 2 (RSV-seronegative infants and children) will remain on study until they complete the post-RSV season visit between April 1 and April 30 in the calendar year following enrollment. Participants in Group 2 will also attend several study visits during the time they are enrolled in the study. Study visits for all participants may include clinical assessments, blood collection, and nasal washes.

Conditions

Respiratory Syncytial Virus Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Group 1: D46cpΔM2-2 Vaccine

RSV-seropositive children will receive a single dose of 10\^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).

Group Type: EXPERIMENTAL

D46cpΔM2-2 vaccine

Intervention Type: BIOLOGICAL

Delivered as nose drops

Group 1: Placebo

RSV-seropositive children will receive a single dose of placebo at study entry (day 0).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Delivered as nose drops

Group 2: D46cpΔM2-2 Vaccine

RSV-seronegative infants and children will receive a single dose of 10\^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).

Group Type: EXPERIMENTAL

D46cpΔM2-2 vaccine

Intervention Type: BIOLOGICAL

Delivered as nose drops

Group 2: Placebo

RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Delivered as nose drops

Interventions

D46cpΔM2-2 vaccine

Delivered as nose drops

Intervention Type: BIOLOGICAL

Placebo

Delivered as nose drops

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Greater than or equal to 12 months of age and less than 60 months of age
• Received routine immunizations appropriate for age
• Serum RSV neutralizing antibody titer greater than or equal to 1:40
• Serum RSV neutralizing antibody result obtained this calendar year
• Pre-inoculation serum RSV neutralizing antibody specimen obtained less than or equal to 56 days prior to inoculation
• Parent/guardian has completed the study comprehension assessment
• Parent/guardian has signed the study informed consent document (ICD)
• Subject is expected to be available for the duration of the study

• Greater than or equal to 6 months of age and less than 25 months of age
• Received routine immunizations appropriate for age
• Serum RSV neutralizing antibody titer is less than 1:40
• Screening and pre-inoculation serum RSV neutralizing antibody specimen obtained less than or equal to 42 days prior to inoculation
• Parent/guardian has completed the study comprehension assessment
• Parent/guardian has signed the study ICD
• Subject is expected to be available for the duration of the study
• Born at greater than or equal to 37 weeks gestation or is currently greater than 1 year of age

Exclusion Criteria

• Evidence of chronic disease
• Within the past 6 months had a decline in height or weight growth that crosses two major growth percentiles (e.g., from above the 75th to below the 25th)
• Known or suspected impairment of immune function
• Maternal history of positive HIV test
• Bone marrow/solid organ transplant recipient
• Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
• Current or unresolved suspected or documented developmental disorder, delay, or other developmental problem
• Cardiac abnormality requiring treatment
• Lung disease or reactive airway disease
• More than one episode of wheezing in the first year of life
• Wheezing episode or received bronchodilator therapy within the past 12 months
• Previous immunization with an experimental RSV vaccine
• Previous receipt or planned administration of anti-RSV antibody product
• Previous serious vaccine-associated AE or anaphylactic reaction
• Known hypersensitivity to any vaccine component
• Previous receipt of immunoglobulin or any antibody products
• Previous receipt of any other blood products within the past 6 months
• Member of a household that contains an infant who is less than 12 months of age during study days 0 to 10
• Member of a household that includes an immunocompromised individual
• Member of a household that includes a person who has received chemotherapy within the past 12 months
• Will attend a daycare facility that does not separate children by age and contains an infant who is greater than 12 months of age during study days 0 to 10

RSV-Seronegative Infants and Children:

• Evidence of chronic disease
• Within the past 6 months had a decline in height or weight growth that crosses two major growth percentiles (e.g., from above the 75th to below the 25th)
• Known or suspected impairment of immune function
• Maternal history of positive HIV test
• Bone marrow/solid organ transplant recipient
• Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
• Current or unresolved suspected or documented developmental disorder, delay, or other developmental problem
• Cardiac abnormality requiring treatment
• Lung disease or reactive airway disease
• More than one episode of wheezing in the first year of life
• Wheezing episode or received bronchodilator therapy within the past 12 months
• Previous immunization with an experimental RSV vaccine
• Previous receipt or planned administration of anti-RSV antibody product
• Previous receipt of immunoglobulin or any antibody products
• Previous receipt of any other blood products within the past 6 months
• Previous serious vaccine-associated AE or anaphylactic reaction
• Known hypersensitivity to any vaccine component
• Member of a household which contains an infant who is less than 6 months of age during study days 0 to 28
• Member of a household that includes an immunocompromised individual
• Member of a household that includes a person who has received chemotherapy within the past 12 months
• Will attend a daycare facility that does not separate children by age and contains an infant who is less than 6 months of age during study days 0 to 28

• Any of the following events at the time of inoculation:

• fever (rectal temperature of greater than or equal to 100.4°F),
• upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis)
• nasal congestion significant enough to interfere with successful inoculation
• otitis media
• Receipt of any killed vaccine or live-attenuated rotavirus vaccine less than 14 days prior to inoculation
• Receipt of the following medications less than 28 days prior to inoculation:

• any live vaccine other than rotavirus
• another investigational vaccine or investigational drug,
• systemic corticosteroids administered for greater than 14 days at a dosage equivalent to prednisone at greater than 2 mg/kg or 20 mg daily
• salicylate (aspirin) or salicylate-containing products
• Receipt of a non-permitted concomitant medication or any of the following medications less than 3 days prior to inoculation:

• systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis,
• intranasal medications
• Scheduled administration of the following in relation to planned inoculation:

• killed vaccine within the 14 days following,
• any live vaccine other than rotavirus within the 28 days following,
• another investigational vaccine or drug within the 28 days following for RSV-seropositive children and the 56 days following for RSV-seronegative infants and children

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 60 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruth A. Karron, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHSPH)

Locations

Johns Hopkins Bloomberg School of Public Health

Baltimore, Maryland, United States

Countries

United States

Provided Documents

Document Type: Informed Consent Form

View Document

Other Identifiers

CIR 308

Identifier Type: -

Identifier Source: org_study_id